Regulatory challenges, reimbursement, and risk-benefit assessment.

Regulatory challenges, reimbursement, and risk-benefit assessment.

Item
http://www.wikidata.org/entity/Q45365048
A practical approach to communicating benefit-risk decisions of medicines to stakeholders.Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.A concise display of multiple end points for benefit-risk assessment.Good decision making requires good communication.Benefit-risk assessment: to quantify or not to quantify, that is the question.Standardizing the Benefit-Risk Assessment of New MedicinesGood Decision Making Requires Good CommunicationApplication of the BRAT Framework to Case Studies: Observations and Insights
P2860

Regulatory challenges, reimbursement, and risk-benefit assessment.

Item
http://www.wikidata.org/entity/Q45365048
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Regulatory challenges, reimbursement, and risk-benefit assessment.
@en
Regulatory challenges, reimbursement, and risk-benefit assessment.
@nl
type
label
Regulatory challenges, reimbursement, and risk-benefit assessment.
@en
Regulatory challenges, reimbursement, and risk-benefit assessment.
@nl
prefLabel
Regulatory challenges, reimbursement, and risk-benefit assessment.
@en
Regulatory challenges, reimbursement, and risk-benefit assessment.
@nl
P1433
P1476
P2093
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P356
P1433
P1476
Regulatory challenges, reimbursement, and risk-benefit assessment.
@en
P2093
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698